Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.47 |
| ▸ | ACACB | O00763 | 1/20 | 0.47 |
| ▸ | ACACA | Q13085 | 1/20 | 0.47 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | CPT2 | P23786 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13062920 | 0.98 | ACE2 (0.50) | LTA4HBLMACE2ACACBACACA | |
| SCHEMBL31444733 | 0.98 | ACE2 (0.50) | LTA4HBLMACE2ACACBACACA | |
| SCHEMBL20825612 | 0.96 | BLM (0.54) | LTA4HBLMACE2ACACBACACA | |
| SCHEMBL8848397 | 0.87 | LTA4H (0.50) | LTA4HBLMACE2ACACBACACA | |
| SCHEMBL27286922 | 0.84 | GABRR1 (0.52) | LTA4HBLMACE2ACACBACACA | |
| SCHEMBL3753790 | 0.84 | GABRR1 (0.52) | LTA4HBLMACE2ACACBACACA | |
| SCHEMBL3259070 | 0.83 | ACACB (0.69) | LTA4HBLMACE2ACACBACACA | |
| SCHEMBL16330413 | 0.83 | BLM (0.65) | LTA4HBLMACE2GABRR1CYP1A2 | |
| SCHEMBL7179523 | 0.83 | BLM (0.65) | LTA4HBLMACE2GABRR1CYP1A2 | |
| SCHEMBL22579908 | 0.83 | ACACB (0.53) | LTA4HBLMACE2ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180140711-A1 | DUOCARMYCIN ADCS SHOWING IMPROVED IN VIVO ANTITUMOR ACTIVITY | SYNTHON BIOPHARMACEUTICALS B.V. (NL) | 2018-05-24 | — | — | US | disclosed |
| US-20170320965-A1 | PAN-REACTIVE ANTIBODIES TO DUOCARMYCINS | SYNTHON BIOPHARMACEUTICALS B.V. (NL) | 2017-11-09 | — | — | US | disclosed |
| US-20170014525-A1 | DUOCARMYCIN ADCS SHOWING IMPROVED IN VIVO ANTITUMOR ACTIVITY | SYNTHON BIOPHARMACEUTICALS B.V. (NL) | 2017-01-19 | — | — | US | disclosed |
| US-20170007717-A1 | DUOCARMYCIN ADCS FOR USE IN TREATMENT OF ENDOMETRIAL CANCER | SYNTHON BIOPHARMACEUTICALS B.V. (NL) | 2017-01-12 | — | — | US | disclosed |
| US-9427480-B2 | Duocarmycin ADCs for use in treatment of endometrial cancer | SYNTHON BIOPHARMACEUTICALS B.V. (NL) | 2016-08-30 | — | — | US | disclosed |
| US-9421278-B2 | Duocarmycin ADCS showing improved in vivo antitumor activity | SYNTHON BIOPHARMACEUTICALS B.V. (NL) | 2016-08-23 | — | — | US | disclosed |
| US-20160008487-A1 | DUOCARMYCIN ADCS FOR USE IN TREATMENT OF ENDOMETRIAL CANCER | BYONDIS B.V. (NL) | 2016-01-14 | — | — | US | disclosed |
| US-20160008486-A1 | DUOCARMYCIN ADCS SHOWING IMPROVED IN VIVO ANTITUMOR ACTIVITY | SYNTHON BIOPHARMACEUTICALS B.V. (NL) | 2016-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160008486-A1 | DUOCARMYCIN ADCS SHOWING IMPROVED IN VIVO ANTITUMOR ACTIVITY | CD38, BRCA1, TP53 | LTA4H 1736/4885BLM 2641/4885ACE2 2943/4885 |
| US-20180140711-A1 | DUOCARMYCIN ADCS SHOWING IMPROVED IN VIVO ANTITUMOR ACTIVITY | CD38, BRCA1, TP53 | LTA4H 1736/4885BLM 2641/4885ACE2 2943/4885 |
| US-20160008487-A1 | DUOCARMYCIN ADCS FOR USE IN TREATMENT OF ENDOMETRIAL CANCER | CD38, MKI67, ACR | LTA4H 3539/4885BLM 4308/4885ACE2 3740/4885 |
| US-20170014525-A1 | DUOCARMYCIN ADCS SHOWING IMPROVED IN VIVO ANTITUMOR ACTIVITY | CD38, BRCA1, TP53 | LTA4H 1736/4885BLM 2641/4885ACE2 2943/4885 |
| US-20170007717-A1 | DUOCARMYCIN ADCS FOR USE IN TREATMENT OF ENDOMETRIAL CANCER | CD38, MKI67, ACR | LTA4H 3539/4885BLM 4308/4885ACE2 3740/4885 |
| US-20170320965-A1 | PAN-REACTIVE ANTIBODIES TO DUOCARMYCINS | GANAB, CNDP2, CD38 | LTA4H 2390/4885BLM 4062/4885ACE2 4448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.